Literature DB >> 18090989

Diverse effects of the CARD15 and IBD5 loci on clinical phenotype in 630 patients with Crohn's disease.

Clive M Onnie1, Sheila A Fisher, Natalie J Prescott, Muddassar M Mirza, Peter Green, Jeremy Sanderson, Alastair Forbes, Cathryn M Lewis, Christopher G Mathew.   

Abstract

OBJECTIVES: Genetic variants at the CARD15 and IBD5 loci are strongly associated with Crohn's disease (CD), but evidence of the effect of these variants on the clinical expression of CD is conflicting and has often been hampered by small sample sizes. We studied 630 well-characterized patients to clarify the genotype/phenotype relationship in CD.
METHODS: Patients and healthy controls were genotyped for three common mutations in CARD15 and a marker of the IBD5 risk haplotype. Allele frequencies were compared between phenotypic subgroups using chi2 or Fisher's exact tests. Genotype/phenotype analysis was carried out using multinomial logistic regression modelling allowing for adjustment for correlated or confounding factors.
RESULTS: The mean age at diagnosis was significantly lower in carriers of the CARD15 or IBD5 risk alleles. After correction for age and smoking, CARD15 mutations were strongly associated with both ileal disease (P=8.8 x 10(-6)) and stenotic disease (P=0.003), but the association with stenotic disease appeared to be due to a confounding effect with ileal disease. CARD15 mutations were also associated with the presence of granulomas (P=5.7 x 10(-5)), which remained significant after adjustment for age at diagnosis and disease location (P=0.0047). The IBD5 risk haplotype frequency was significantly elevated in cases with perianal disease (P=0.028) and axial spondyloarthropathy (P=0.012).
CONCLUSION: Genetic variants at the CARD15 and IBD5 loci have diverse effects on clinical expression in CD. CARD15 mutations are significantly correlated with the presence of granulomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18090989     DOI: 10.1097/MEG.0b013e3282f1622b

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

1.  Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohn's disease risk in a population-based case-control study: evidence of gene-gene interactions.

Authors:  Toshihiko Okazaki; Ming-Hsi Wang; Patricia Rawsthorne; Michael Sargent; Lisa Wu Datta; Yin Yao Shugart; Charles N Bernstein; Steven R Brant
Journal:  Inflamm Bowel Dis       Date:  2008-11       Impact factor: 5.325

2.  Searching for genotype-phenotype structure: using hierarchical log-linear models in Crohn disease.

Authors:  Juliet M Chapman; Clive M Onnie; Natalie J Prescott; Sheila A Fisher; John C Mansfield; Christopher G Mathew; Cathryn M Lewis; Claudio J Verzilli; John C Whittaker
Journal:  Am J Hum Genet       Date:  2009-01-29       Impact factor: 11.025

3.  Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review.

Authors:  Calen A Steiner; Jeffrey A Berinstein; Jeremy Louissaint; Peter D R Higgins; Jason R Spence; Carol Shannon; Cathy Lu; Ryan W Stidham; Joel G Fletcher; David H Bruining; Brian G Feagan; Vipul Jairath; Mark E Baker; Dominik Bettenworth; Florian Rieder
Journal:  Clin Gastroenterol Hepatol       Date:  2021-06-02       Impact factor: 11.382

4.  Genetic Association Analysis Reveals Differences in the Contribution of NOD2 Variants to the Clinical Phenotypes of Orofacial Granulomatosis.

Authors:  Alexander Mentzer; Shalini Nayee; Yasmin Omar; Esther Hullah; Kirstin Taylor; Rishi Goel; Hannah Bye; Tarik Shembesh; Timothy R Elliott; Helen Campbell; Pritash Patel; Anita Nolan; John Mansfield; Stephen Challacombe; Michael Escudier; Christopher G Mathew; Jeremy D Sanderson; Natalie J Prescott
Journal:  Inflamm Bowel Dis       Date:  2016-07       Impact factor: 5.325

5.  Long-Term Follow-Up, Association between CARD15/NOD2 Polymorphisms, and Clinical Disease Behavior in Crohn's Disease Surgical Patients.

Authors:  Francesco Giudici; Tiziana Cavalli; Cristina Luceri; Edda Russo; Daniela Zambonin; Stefano Scaringi; Ferdinando Ficari; Marilena Fazi; Amedeo Amedei; Francesco Tonelli; Cecilia Malentacchi
Journal:  Mediators Inflamm       Date:  2021-02-24       Impact factor: 4.711

6.  Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases.

Authors:  Joana Torres; Flavio Caprioli; Konstantinos H Katsanos; Triana Lobatón; Dejan Micic; Marco Zerôncio; Gert Van Assche; James C Lee; James O Lindsay; David T Rubin; Remo Panaccione; Jean-Frédéric Colombel
Journal:  J Crohns Colitis       Date:  2016-06-09       Impact factor: 9.071

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.